Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Insights into uveitis in association with spondyloarthritis from a large patient survey.

Keck KM, Choi D, Savage LM, Rosenbaum JT.

J Clin Rheumatol. 2014 Apr;20(3):141-5. doi: 10.1097/RHU.0000000000000087.

PMID:
24662555
2.

Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.

Gao X, Wendling D, Botteman MF, Carter JA, Rao S, Cifaldi M.

J Med Econ. 2012;15(6):1054-63. doi: 10.3111/13696998.2012.692341. Epub 2012 Jun 11.

PMID:
22563743
3.

A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial.

Dougados M, Combe B, Braun J, Landewé R, Sibilia J, Cantagrel A, Feydy A, van der Heijde D, Leblanc V, Logeart I.

Ann Rheum Dis. 2010 Aug;69(8):1430-5. doi: 10.1136/ard.2009.121533. Epub 2010 May 28.

PMID:
20511606
4.

Early increase of abdominal adiposity in patients with spondyloarthritis receiving anti-tumor necrosis factor-α treatment.

Hmamouchi I, Roux C, Paternotte S, Kolta S, Dougados M, Briot K.

J Rheumatol. 2014 Jun;41(6):1112-7. doi: 10.3899/jrheum.131150. Epub 2014 Apr 15. Erratum in: J Rheumatol. 2014 Nov;41(11):2336.

PMID:
24737911
5.

Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis.

Maksymowych WP, Inman RD, Gladman D, Thomson G, Stone M, Karsh J, Russell AS; Spondyloarthritis Research Consortium of Canada (SPARCC).

J Rheumatol. 2003 Jun;30(6):1356-63. Review.

PMID:
12784417
6.

Uveitis and tumour necrosis factor blockade in ankylosing spondylitis.

Coates LC, McGonagle DG, Bennett AN, Emery P, Marzo-Ortega H.

Ann Rheum Dis. 2008 May;67(5):729-30. doi: 10.1136/ard.2007.077370. No abstract available.

PMID:
18408116
7.

Infection relapse in spondyloarthritis treated with biological drugs: a single-centre study.

Modesti V, Ramonda R, Ortolan A, Lorenzin M, Lo Nigro A, Frallonardo P, Oliviero F, Campana C, Punzi L.

Scand J Rheumatol. 2012;41(6):490-1. doi: 10.3109/03009742.2012.698393. Epub 2012 Sep 18. No abstract available.

PMID:
22985209
8.

Body weight, gender and response to TNF-α blockers in axial spondyloarthritis.

Gremese E, Bernardi S, Bonazza S, Nowik M, Peluso G, Massara A, Tolusso B, Messuti L, Miceli MC, Zoli A, Trotta F, Govoni M, Ferraccioli G.

Rheumatology (Oxford). 2014 May;53(5):875-81. doi: 10.1093/rheumatology/ket433. Epub 2014 Jan 9.

PMID:
24407233
9.

Pathophysiology and role of the gastrointestinal system in spondyloarthritides.

Jacques P, Van Praet L, Carron P, Van den Bosch F, Elewaut D.

Rheum Dis Clin North Am. 2012 Aug;38(3):569-82. doi: 10.1016/j.rdc.2012.08.012. Epub 2012 Sep 13. Review.

PMID:
23083756
10.

Anti-TNFα agents and methotrexate in spondyloarthritis related uveitis in a Chinese population.

Lian F, Zhou J, Wei C, Wang Y, Xu H, Liang L, Yang X.

Clin Rheumatol. 2015 Nov;34(11):1913-20. doi: 10.1007/s10067-015-2989-8. Epub 2015 Jun 13.

PMID:
26070537
11.

Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis.

Tynjälä P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K.

Ann Rheum Dis. 2007 Apr;66(4):548-50. Epub 2006 Oct 26.

12.

Biological drug treatment of rheumatoid arthritis and spondyloarthritis: effects on QT interval and QT dispersion.

DI Franco M, Paradiso M, Ceccarelli F, Scrivo R, Spinelli FR, Iannuccelli C, Valesini G.

J Rheumatol. 2012 Jan;39(1):41-5. doi: 10.3899/jrheum.110158. Epub 2011 Nov 1.

PMID:
22045840
13.

Extra-articular disease in patients with spondyloarthritis. Baseline characteristics of the spondyloarthritis cohort of the AQUILES study.

Zarco P, González CM, Rodríguez de la Serna A, Peiró E, Mateo I, Linares L, Calvo J, Cea-Calvo L, Arteaga MJ, Vanaclocha F, Marín-Jiménez I, García-Vicuña R.

Reumatol Clin. 2015 Mar-Apr;11(2):83-9. doi: 10.1016/j.reuma.2014.04.003. Epub 2014 Nov 11. English, Spanish.

14.

Impact of uveitis on the phenotype of patients with recent inflammatory back pain: data from a prospective multicenter French cohort.

Wendling D, Prati C, Demattei C, Miceli-Richard C, Daures JP, Dougados M.

Arthritis Care Res (Hoboken). 2012 Jul;64(7):1089-93. doi: 10.1002/acr.21648.

15.

Acute anterior uveitis and other extra-articular manifestations of spondyloarthritis.

Mitulescu TC, Popescu C, Naie A, Predeţeanu D, Popescu V, Alexandrescu C, Voinea LM.

J Med Life. 2015 Jul-Sep;8(3):319-25.

16.

Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment.

Kakkassery V, Mergler S, Pleyer U.

Curr Eye Res. 2010 Aug;35(8):751-6. doi: 10.3109/02713683.2010.486520.

PMID:
20673052
17.

Recurrent uveitis in a patient with juvenile spondyloarthropathy associated with tumour necrosis factor alpha inhibitors.

Kaipiainen-Seppänen O, Leino M.

Ann Rheum Dis. 2003 Jan;62(1):88-9. Review. No abstract available.

18.

Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.

Collamer AN, Battafarano DF.

Semin Arthritis Rheum. 2010 Dec;40(3):233-40. doi: 10.1016/j.semarthrit.2010.04.003. Epub 2010 Jun 26. Review.

PMID:
20580412
19.

Do tumor necrosis factor inhibitors cause uveitis? A registry-based study.

Lim LL, Fraunfelder FW, Rosenbaum JT.

Arthritis Rheum. 2007 Oct;56(10):3248-52.

20.

Early tumor necrosis factor α antagonist therapy in everyday practice for inflammatory back pain suggesting axial spondyloarthritis: results from a prospective multicenter french cohort.

Canouï-Poitrine F, Poulain C, Molto A, Le Thuaut A, Lafon C, Farrenq V, Ferkal S, Le Corvoisier P, Ghaleh B, Bastuji-Garin S, Fautrel B, Dougados M, Claudepierre P.

Arthritis Care Res (Hoboken). 2014 Sep;66(9):1395-402. doi: 10.1002/acr.22330.

Supplemental Content

Support Center